DNTH - Dianthus Therapeutics, Inc.
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on May 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr.
NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on April 1, 2026, to eight newly-hired, non-executive employees.
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero.
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,124 shares of the company's stock after purchasing an additional 58,746 shares during
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating
SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Profitability This table compares SELLAS Life
5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal filing with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a legal filing with the SEC, which
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,157,407 shares, at a public offering price of $81.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering were approximately $719 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus. All of the securities were offered by Dianthus.
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.